参考文献/References:
[1] Inagaki T,Choi M,Moschetta A,et al.Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis[J].Cell Metab,2005,2(4):217-225.
[2] Aguilar MT,Chascsa DM.Update on emerging treatment options for primary biliary cholangitis[J].Hepat Med,2020,12:69-77.
[3] 苏保伟,王景杰.胆汁反流性胃炎发病机制及其肠化生分子作用机制研究进展[J].陕西医学杂志,2020,49(9):1199-1201.
[4] Russell DW.Fifty years of advances in bile acid synthesis and metabolism[J].J Lipid Res,2009,50:120-125.
[5] Ge MX,Shao RG,He HW.Advances in understanding the regulatory mechanism of cholesterol 7 alpha-hydroxylase[J].Biochem Pharmacol,2019,164:152-164.
[6] Stroup D,Crestani M,Chiang JY.Identification of a bile acid response element in the cholesterol 7 alpha-hydroxylase gene CYP7A[J].Am J Physiol,1997,273(2):508-517.
[7] Li M,Wang Q,Li Y,et al.Apical sodium-dependent bile acid transporter,drug target for bile acid related diseases and delivery target for prodrugs:Current and future challenges[J].Pharmacol Ther,2020,212:107539.
[8] Stroup D,Chiang JY.HNF4 and COUP-TFII interact to modulate transcription of the cholesterol 7 alpha-hydroxylase gene(CYP7A1)[J].J Lipid Res,2000,41(1):1-11.
[9] Bajor A,Gillberg PG,Abrahamsson H.Bile acids:Short and long term effects in the intestine[J].Scand J Gastroenterol,2010,45(6):645-664.
[10] Drozdzik M,Gröer C,Penski J,et al.Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine[J].Mol Pharm,2014,11(10):3547-3555.
[11] Luo ZL,Cheng L,Wang T,et al.Bile acid transporters are expressed and heterogeneously distributed in rat bile ducts[J].Gut Liver,2019,13(5):569-575.
[12] Thomas C,Landrier JF,Gaillard D,et al.Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter(ASBT)gene expression:Molecular mechanism and physiological consequences[J].Gut,2006,55(9):1321-1331.
[13] Walker NJ.Real-time and quantitative PCR:Applications to mechanism-based toxicology[J].Journal of Biochemical and Molecular Toxicology,2001,15(3):121-127.
[14] Peppel IP,Verkade HJ,Jonker JW.Multiple factors regulate the rat liver basolateral sodium-dependent bile acid cotransporter gene promoter[J].J Biol Chem,1996,271(25):15211-15221.
[15] Neimark E,Chen F,Li X.Bile acid-induced negative feedback regulation of the human ileal bile acid transporter[J].Hepatology,2004,40:149-156.
[16] Chen X,Chen F,Liu S,et al.Transactivation of rat apical sodium-dependent bile acid transporter and increased bile acid transport by 1alpha,25-dihydroxyvitamin D3 via the vitamin dreceptor[J].Mol Pharmacol,2006,69:1913-1923.
[17] Liu J,Sempos CT,Donahue RP,et al.Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease[J].Am J Cardiol,2006,98:1363-1368.
[18] Peppel IP,Verkade HJ,Jonker JW.Metabolic consequences of ileal interruption of the enterohepatic circulation of bile acids[J].Am J Physiol Gastrointest Liver Physiol,2020,319(5):619-625.
[19] Sauer P,Stiehl A,Fitscher BA,et al.Downregulation of ileal bile acid absorption in bile-duct-ligated rats[J].J Hepatol,2000,33:2-8.
[20] Hu NJ,Iwata S,Cameron AD,et al.Crystal structure of abacterial homologue of the bile acid sodium symporter ASBT[J].Nature,2011,478:408-411.
[21] Ou X,Yang H,Ramani K,et al.Inhibition of human betaine-homocysteine methyltransferase expression by S-adenosylmethionine and methylthioadenosine[J].Biochemical Journal,2007,401(1):87-96.
[22] Hou RG,Fan L,Liu JJ,et al.Bile acid malabsorption is associated with diarrhea in acute phase of colitis[J].Can J Physiol Pharmacol,2018,96(12):1328-1336.
[23] Ding L,Yang L,Wang Z,et al.Bile acid nuclear receptor FXR and digestive system diseases[J].Acta Pharmaceutica Sinica B,2015,5(2):135-144.
[24] Chen L,Yao X,Young A,et al.Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes[J].Am J Physiol Endocrinol Metab,2012,302(1):e68-e76.
[25] Kannel WB,Castelli WP,Gordon T.Cholesterol in the prediction of atherosclerotic disease.New perspectives based on the Framingham study[J].Ann Intern Med,1979,90(1):85-91.
[26] Matye DJ,Wang H,Luo W,et al.Combined ASBT inhibitor and FGF15 treatment improves therapeutic efficacy in experimental nonalcoholic steatohepatitis[J].Cell Mol Gastroenterol Hepatol,2021,12(3):1001-1019.
[27] Tomlinson E,Fu L,John L,et al.Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity[J].Endocrinology,2002,143(5):1741-1747.
[28] Luo J,Ko B,Elliott M,et al.A nontumorigenic variant of FGF19 treats cholestatic liver diseases[J].Sci Transl Med,2014,6(247):100-108.
[29] Fickert P,Pollheimer MJ,Silbert D,et al.Differential effects of norUDCA and UDCA in obstructive cholestasis in mice[J].J Hepatol,2013,58(6):1201-1208.
[30] 王新伟,杨道坤,梁海军,等.熊去氧胆酸对慢性乙型肝炎患者NAs抗病毒治疗后肝功能异常修复的临床研究[J].陕西医学杂志,2020,49(1):112-114.